CRSP Stock Summary and Trading Ideas (Crispr Therapeutics Ag - Common Shares | NASDAQ:CRSP)

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Crispr Therapeutics Ag - Common Shares trades on the NASDAQ stock market under the symbol CRSP.

As of July 17, 2026, CRSP stock price declined to $47.76 with 972,600 million shares trading.

CRSP has a beta of 1.85, meaning it tends to be more sensitive to market movements. CRSP has a correlation of 0.14 to the broad based SPY ETF.

CRSP has a market cap of $4.70 billion. This is considered a Mid Cap stock.

Last quarter Crispr Therapeutics Ag - Common Shares reported $1 million in Revenue and -$1.28 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.06.

In the last 3 years, CRSP traded as high as $91.10 and as low as $30.04.

The top ETF exchange traded funds that CRSP belongs to (by Net Assets): ARKK, ARKE, IWM, ARKG, XBI.

CRSP has underperformed the market in the last year with a price return of -13.4% while the SPY ETF gained +20.3%. CRSP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -14.3% and -20.5%, respectively, while the SPY returned +6.2% and -0.2%, respectively.

CRSP support price is $46.72 and resistance is $50.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRSP shares will trade within this expected range on the day.